Table 1. Baseline Characteristics.
| Variable | Sample sizes (if different) | Usual Care (N=45) | Telemonitor (N=54) |
|---|---|---|---|
| Patient Demographics | |||
| Age (yrs), mean ± SD | 74.7 ± 11.3 | 75.0 ± 12.1 | |
| Female, n (%) | 27 (60.0) | 40 (74.1) | |
| African American Race, n (%) | 12 (26.7) | 9 (16.7) | |
| Ischemic HF etiology, n (%) | 39, 44 | 27 (69.2) | 32 (72.7) |
| Systolic HF type, n (%) | 36, 42 | 11 (30.6) | 20 (47.6) |
| NYHA Class*, n (%) | |||
| NYHA II | 43, 53 | 19 (44.2) | 22 (41.5) |
| NYHA III | 20 (46.5) | 28 (52.8) | |
| NYHA IV | 4 (9.3) | 3 (5.7) | |
| KCCQ, mean ± SD | |||
| Overall Summary Score | 43, 52 | 36.4 ± 18.0 | 36.0 ± 21.7 |
| Clinical Summary Score | 43, 52 | 37.7 ± 20.7 | 35.4 ± 22.0 |
| Comorbidities, n (%) | |||
| Diabetes** | 28 (62.2) | 23 (42.6) | |
| Anemia | 4 (8.9) | 6 (11.1) | |
| Hypertension | 24 (53.3) | 25 (46.3) | |
| CAD | 15 (33.3) | 17 (31.5) | |
| AFib | 15 (33.3) | 27 (50.0) | |
| COPD | 15 (33.3) | 18 (33.3) | |
| Acute infection(UTI, Pneumonia) | 6 (13.3) | 3 (5.6) | |
| Chronic Kidney Disease | 7 (15.6) | 5 (9.3) | |
| Chronic Skin Ulcer | 3 (6.7) | 4 (7.4) | |
| Gen Muscle Weak/Fatigue | 20 (44.4) | 22 (40.7) | |
| Medications and Dosage‡ | |||
| Enalapril eq., n (%) | 14 (31.1) | 23 (42.6) | |
| Daily dose, mg | 25.7 (2.5, 20, 80) | 20.3 (2.5, 10, 100) | |
| Valsartan eq., n (%) | 13 (28.9) | 13 (24.1) | |
| Daily dose, mg | 240 (80, 320, 320) | 194 (40, 160, 640) | |
| Metoprolol eq., n (%) | 37 (82.2) | 42 (77.8) | |
| Daily dose, mg | 93.9 (12.5,100,320) | 92.0 (12.5, 87.5, 400) | |
| Furosemide eq., n (%) | 40 (88.9) | 43 (79.6) | |
| Daily dose, mg | 104.5 (20, 80, 480) | 60.9 (20, 40, 320) |
*
NYHA- New York Heart Association Class
Class I – Asymptomatic
Class II – Symptomatic with usual activity
Class III – Symptomatic with minimal activity
Class IV – Symptomatic at rest
**
difference in number of diabetics between groups p=0.05
‡
Medication daily doses are mean (min, median, max).